Study on Development of Novel Cancer Vaccine Using Hybrid Liposomes

• Project/Area Number: 25420842
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Biofunction/Bioprocess
• Research Institution: Sojo University
• Principal Investigator: GOTO Koichi 崇城大学, 生物生命学部, 教授 (30279377)
• Co-Investigator(Kenkyū-buntansha): 上岡 龍一 崇城大学, 生物生命学部, 研究員 (70099076)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: がん / ワクチン / リポソーム / 免疫 / 癌

Outline of Final Research Achievements

In this study, we examined the induction effects of hybrid liposomes (HL-MUC-1/mB7-1) composed of phospholipids (DMPC) and nonionic surfactants (Tween 80) including synthetic mucin MUC-1 antigen peptides and recombinant mB7-1 membrane proteins on the cancer immunotherapy in vitro and in vivo. CD8+ T cells from the mice intravenously administrated HL-MUC-1/mB7-1 had a tendency to increase the cytotoxicity to the breast cancer cells in vitro, and the prolonged survival was observed in mice implanted with breast cancer cells after the administration of HL-MUC1/mB7-1, suggesting the possibility of novel cancer vaccine using hybrid liposomes.